Improved outcome in tobacco smoking patients with non-small cell lung cancer (NSCLC) following immunotherapy has previously been reported. However, little is known regarding this association during first-line immunotherapy in patients with high PD-L1 expression. In this study we compared clinical outcomes according to the smoking status of two large multicenter cohorts.
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: a case-control matched analysis from a large multicenter study / Cortellini, A., De Giglio, A., Cannita, K., Cortinovis, D.L., Cornelissen, R., Baldessari, C., Giusti, R., D'Argento, E., Grossi, F., Santoni, M., Catino, A., Berardi, R., Sforza, V., Rossi, G., Antonuzzo, L., Di Noia, V., Signorelli, D., Gelibter, A., Occhipinti, M., Follador, A., et al.. - In: THORACIC CANCER. - ISSN 1759-7714. - 12:6(2021), pp. 880-889. [10.1111/1759-7714.13852]
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: a case-control matched analysis from a large multicenter study
Gelibter, Alain;Occhipinti, Mario;Zoratto, Federica;Filetti, Marco;Napoli, Valerio Maria;
2021
Abstract
Improved outcome in tobacco smoking patients with non-small cell lung cancer (NSCLC) following immunotherapy has previously been reported. However, little is known regarding this association during first-line immunotherapy in patients with high PD-L1 expression. In this study we compared clinical outcomes according to the smoking status of two large multicenter cohorts.| File | Dimensione | Formato | |
|---|---|---|---|
|
Cortellini_Smoking-status_2021.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
2.1 MB
Formato
Adobe PDF
|
2.1 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
